🚨🔥 ABSOLUTELY STUNNING! DeLLphi-305 at #ESMO26!
@sands_jacob presents remarkable phase III results in ES-SCLC!
💥 Tarlatamab + durvalumab vs durvalumab maintenance
🔥 Median OS: 21.1 vs 12.7 months
🔥 HR 0.42 (95% CI 0.32–0.54), p<0.001
🔥 12-month OS: 79% vs 53%
58% reduction in the hazard of death!
These are extraordinary results in a disease where meaningful survival advances have been so difficult to achieve.
👏 Congratulations and I welcome
A new benchmark for ES-SCLC maintenance therapy
#ESMOAmbassadors #ESMO26 #SCLC #LungCancer #DeLLphi305
92 浏览 · 2 赞 · 0 转发 · 0 回复
Tarlatamab plus durvalumab (durva) vs durva as 1L maintenance (1LM) therapy following durva, platinum, and etoposide (1L durva + EP) in extensive-stage small cell lung cancer (ES-SCLC): Primary analysis of the phase 3 DeLLphi-305 trial
https://esmocongress.esmo.org来源：Alfredo Addeo MD · x.com